Comparison of Efficacy and Complication of Alteplase Injection in Acute Ischemic Stroke

Alteplase is a thrombolytic drug that is produced by recombinant DNA technology. Tissue plasminogen activator enzymewhich converts plasminogen to the active form of plasmin is also produced by the same technology; it causes fibrinolysis and clot dissolution. This study aimed to compare the efficacy and complications of Alteplase injection in patients with acute ischemicstroke (AIS(during the first 3hours and 3-4.5hours after the onset of symptoms.

In this study, patients with AIS who were referred to Golestan Hospital of Ahvaz city during 2018-2019 were selected. Information was collected by a checklist.

The results showed that the mean Modified Rankin Scale(mRS)for 3 months and 6 months (p-value: 0.91 for 3months and p-value: 0.80 for 6months) and National Institutes of Health Stroke Scale(NIHSS)(p-value: 0.21) were not significantly different between both groups; statistically, no significant relationship was observed between them. The incidence of complications after treatment was almost similar, in both groups.

Finally, it was concluded that complications and efficacy of rt-PA (Alteplase) injection were not statistically different, between the two groups under study.